Tracon Scoops FDA Orphan Drug Designation for TRC105

The FDA has smiled on Tracon Pharmaceuticals with orphan drug designation for its TRC105 to treat soft tissue sarcoma.

TRC105 is an antibody to endoglin, a protein overexpressed on proliferating endothelial cells. It is being studied in Phase 2 clinical trials for the treatment of multiple solid tumor types in combination with VEGF inhibitors. The company plans to initiate a pivotal Phase 3 trial in patients with angiosarcoma in 2016.